This proposal is Project 4 of a P50 application for the proposed Center for Interdisciplinary Research in Nicotine Addiction (CIRNA). Development of robust new medications for smoking cessation is hampered in part by inefficiency in how they are initially screened for efficacy in humans. Building on our prior work, this proposal is aimed at improving the sensitivity of procedures for screening medication efficacy. Within practical limits, such screening should simulate clinical trial methods, including use of smoking abstinence as the primary index of medication response, which may require study participants who are motivated to abstain, at least briefly. In prior research, we found that medication (NRT patch) increased abstinence over one week of use in treatment seekers, those with high intrinsic quit motivation, but extrinsic quit motivation via reinforcement for abstinence made no difference. Although informative, our findings are preliminary until they can be cross-validated with other cessation medications, which is the focus of the current project. Study 1 will examine in 200 smokers whether these results generalize to another effective medication, varenicline, by using the same mixed, cross-over design, with treatment seeking status and abstinence reinforcement as 2x2 between-subjects factors, and varenicline vs placebo as a within-subject factor. We predict that varenicline (vs placebo) will increase abstinence (i.e., show efficacy) over one week in treatment seekers more than in non-treatment seekers, confirming the importance of intrinsic quit motivation for screening. Study 2 will determine whether use of treatment seekers in such screening is both sensitive and specific. Sensitivity will be indicated if our procedure shows efficacy with another medication known to aid cessation in clinical trials, bupropion (i.e., a positive control), while specificity will be indicated if our procedure shows no efficacy in a medication known not to be effective for cessation in clinical trials, in this case modafinil (i.e., a negative control). Treatment seekers (n=100) will receive each medication and placebo in a within-subject cross-over design. We predict that, compared with placebo, bupropion will increase abstinence. Efficacy of modafinil, which is not expected, would question our procedure's specificity. Secondarily, both studies will examine individual differences and medication effects on symptoms of early abstinence (craving, withdrawal, negative and positive affect, smoking reward) to determine possible mechanisms of efficacy. Results will provide immediate directions for improving the screening of novel cessation medications, the project's longrange objective and a goal with very high public health significance.

Public Health Relevance

Progress in medication development for smoking cessation is partly limited by the lack of a valid, quick screening procedure to ensure that promising drugs proceed to clinical trials and unpromising drugs do not. This project will build on our prior research to verify the sensitivity and specificity of a new procedure to detect which drugs will or will not likely help smokers quit. This research will increase the efficiency of screening novel drugs, hastening the delivery of effective new medications to smokers needing help to quit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA143187-05
Application #
8530983
Study Section
Special Emphasis Panel (ZDA1-RXL-E)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$260,333
Indirect Cost
$79,295
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ashare, Rebecca L; Lerman, Caryn; Cao, Wen et al. (2016) Nicotine withdrawal alters neural responses to psychosocial stress. Psychopharmacology (Berl) 233:2459-67
Forcelli, Patrick A; Turner, Jill R; Lee, Bridgin G et al. (2016) Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology 101:46-56
Schnoll, Robert A; Hitsman, Brian; Blazekovic, Sonja et al. (2016) Longitudinal changes in smoking abstinence symptoms and alternative reinforcers predict long-term smoking cessation outcomes. Drug Alcohol Depend 165:245-52
Strasser, Andrew A; Souprountchouk, Valentina; Kaufmann, Amanda et al. (2016) Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tob Regul Sci 2:352-362
Perkins, Kenneth A; Karelitz, Joshua L; Michael, Valerie C et al. (2016) Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. Nicotine Tob Res 18:74-8
Ashare, R L; Kimmey, B A; Rupprecht, L E et al. (2016) Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers. Transl Psychiatry 6:e713
Lee, Bridgin G; Anastasia, Agustin; Hempstead, Barbara L et al. (2015) Effects of the BDNF Val66Met Polymorphism on Anxiety-Like Behavior Following Nicotine Withdrawal in Mice. Nicotine Tob Res 17:1428-35
Falcone, M; Bansal-Travers, M; Sanborn, P M et al. (2015) Awareness of FDA-mandated cigarette packaging changes among smokers of 'light' cigarettes. Health Educ Res 30:81-6
Jhanjee, Sonali; Jain, Raka; Jain, Veena et al. (2015) Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India. J Psychoactive Drugs 47:325-30
Jain, Raka; Jhanjee, Sonali; Jain, Veena et al. (2015) Biochemical Validation of Self-Reported Smokeless Tobacco Abstinence among Smokeless Tobacco Users: Results from a Clinical Trial of Varenicline in India. J Psychoactive Drugs 47:331-5

Showing the most recent 10 out of 104 publications